Home

Mark Christopher Capone

CIK 1352413 · President & C.E.O. · last filed 2026-08-17

Mark Christopher Capone is a President & C.E.O. who has filed 58 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for MLAB, was dated Aug 17, 2026. Across all open-market trades the lifetime net is −$30.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.6M across reported positions. 54 SEC filings were submitted jointly with MYRIAD GENETICS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.63M

Companies

4

Total Filings

58

Lifetime Open-Market Net

-$30.69M

Filer Profile

Reported Address
320 WAKARA WAY
SALT LAKE CITY, UT 84108
Related Filers
MYRIAD GENETICS INC — 54 joint filings, latest 2019-10-01
MESA LABORATORIES INC /CO/ — 6 joint filings, latest 2026-08-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MLAB Director 6,213 $120.87 $751.0K $99.3K 5 2026-08-17
SERA Director 44,379 $2.03 $90.1K $0 1 2026-07-14
DermTech, Inc. (DMTK) Delisted Director 82,054 $0.09 $7.7K $0 2 2023-06-05
MYGN President & C.E.O. 522,216 $3.42 $1.79M -$30.79M 50 2019-10-01

Recent Filings

58 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-17 MLAB Exer (M) +2,784 $0 EDGAR
2026-07-14 SERA Grant (A) +44,379 $0 EDGAR
2026-03-10 MLAB Buy (P) +1,301 $99.3K EDGAR
2025-08-18 MLAB Mixed +1,404 $0 EDGAR
2024-08-19 MLAB Mixed +724 $0 EDGAR
2024-02-16 MLAB Grant (A) — $0 EDGAR
2023-06-05 DermTech, Inc. (DMTK) Delisted Grant (A) +35,714 $0 EDGAR
2022-07-20 DermTech, Inc. (DMTK) Delisted Grant (A) +46,340 $0 EDGAR
2019-10-01 MYGN Disp (D) −27,022 -$773.6K EDGAR
2019-09-26 MYGN Mixed +108,405 -$1.02M EDGAR
Showing 1–10 of 58
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.